Your browser doesn't support javascript.
loading
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
Handolias, D; Hamilton, A L; Salemi, R; Tan, A; Moodie, K; Kerr, L; Dobrovic, A; McArthur, G A.
Affiliation
  • Handolias D; Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Br J Cancer ; 102(8): 1219-23, 2010 Apr 13.
Article in En | MEDLINE | ID: mdl-20372153
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyridines / Pyrimidines / Skin Neoplasms / Benzenesulfonates / Melanoma / Antineoplastic Agents Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Br J Cancer Year: 2010 Document type: Article Affiliation country: Australia Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyridines / Pyrimidines / Skin Neoplasms / Benzenesulfonates / Melanoma / Antineoplastic Agents Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Br J Cancer Year: 2010 Document type: Article Affiliation country: Australia Country of publication: Reino Unido